After Coldrif was linked to children's death in India, regulators have now advised against the use of two more cough syrups including Respifresh TR and ReLife. The World Health Organization (WHO) has also warned of the potential risks of the unregulated channels through which these cough syrups could be exported, however, as of now, these have not been exported. Health alerts from Gujarat and other states describe both Respifresh and ReLife as containing DEG, “a toxic chemical that can cause serious poisoning, including kidney failure, neurological complications, and even death, particularly in children.”Read: Cough Syrup Row: Death Toll Rise To 22 As 2 More Children SuccumbThe Jammu And Kashmir Cough Syrup Death CaseHowever, this is not the first case of cough syrup linked deaths of children from India. Earlier, between 2019 and 2020, at least 12 children under five died in Jammu and Kashmir, allegedly from cough syrup. The syrup has been manufactured in Himachal Pradesh's Sirmaur district by pharmaceutical company Digital Vision. Scroll reported that Digital Vision has "not only gone to resume production, but found guilt of more drug quality violations." The samples of the cough syrups were collected in Ramnagar and sent to lab for tests in Chandigarh. The tests found that "more 34% diethylene glycol", said Jammu and Kashmir drug controller Lotika Khajuria to BBC. The samples' findings were also corroborated by another Kolkata-based lab test, said Khajuria. The BBC report mentioned that the toxins failed the children's kidneys, and in some cases, even multiple organs were affected, including brain, liver, and lungs. Some of the children were also to be put on ventilators, while some were left with major disabilities.Also Read: What Does Trump's Latest Health Checkup Reveal About Him? The Gambia Cough Syrup Death CaseIn the September of 2022, reports BBC, a father in The Gambia, watched his young son slowly die in front of his eye. His son, 3-year-pld Lamin was among the 70 children, younger than five, who died in The Gambia of acute kidney injuries between July and October of 2022. All these kids consumed one of the four cough syrups made by an Indian company called Maiden Pharmaceuticals. In fact, in October 2022, the WHO linked the deaths to the syrups and said that it found "unacceptable" levels of toxins in the medicines. A Gambian parliamentary panel also concluded after investigations that the deaths were the result of children ingesting the syrups. However, the pharmaceutical company denied this and said that the cough syrups complied with quality standards when tested domestically. Though the then chairperson of the Gambian panel that investigated these deaths Amadou Camara strongly denied. He said, "We have evidence. We tested these drugs. [They] contained unacceptable amounts of ethylene glycol and diethylene glycol, and these were directly imported from India, manufactured by Maiden."Ethylene glycol and diethylene glycol are toxic to humans and could be fatal if consumed.Uzbekistan Cough Syrup Death CaseAfter the trial of August 2023, an Uzbekistan court sentenced 23 people to prison over the deaths of 68 children linked to contaminated cough syrup. Among them were Singh Ragvendra Pratar, reports BBC, who was given the longest sentence of 20 years. He was the executive director at Quaramax Medical, who distributed the contaminated cough syrups manufactured by Marion Biotech in India. WHO in January 2023, also said that the products manufactured by Marion Biotech were "substandard" and that the firm had failed to provide guarantees about their safety. After this, India's health ministry suspended production at the company. The authorities stated that they were "permanently" cancelling the company's license.